PRKAG2 Syndrome

checkorphan

Synonyms

PRKAG2-related cardiomyopathy , PRKAG2 cardiac syndrome, PRKAG2 cardiomyopathy,

Overview

PRKAG2 syndrome is a rare, autosomal dominant genetic glycogen storage disease. It is caused by mutations in the PRKAG2 gene, which alters AMPK enzyme function, leading to massive glycogen buildup in heart cells. Key features include severe heart muscle thickening, Wolff-Parkinson-White (WPW) syndrome, and progressive heart block.

Symptoms

Symptoms typically begin in adulthood (around age 30) and include:

  • Arrhythmias: Palpitations, rapid heartbeats (atrial fibrillation/flutter), and Wolff-Parkinson-White (WPW) syndrome.
  • Conduction blocks: Dizziness, fainting (syncope), and the heart’s inability to increase its rate during exercise.
  • Cardiomyopathy: Shortness of breath, chest pain, and heart muscle thickening that mimics hypertrophic cardiomyopathy.
  • Skeletal muscle involvement: General muscle weakness and exercise-induced muscle pain (myalgia).

Causes

PRKAG2 syndrome is a rare genetic disorder caused by mutations in the PRKAG2 gene, which provides instructions for making a subunit of the AMPK enzyme. These mutations lead to overactive AMPK, causing glycogen to accumulate excessively in the heart, resulting in thickened heart muscles and irregular electrical rhythms.

Prevention

Because PRKAG2 syndrome is an inherited genetic disorder, true “prevention” focuses on family planning, early screening, and preemptive medical intervention. The condition leads to severe cardiac glycogen buildup, arrhythmias, and heart enlargement, meaning preemptive care is crucial to stop life-threatening complications.

Diagnosis

Diagnosing PRKAG2 Syndrome relies on a multimodal approach combining clinical evaluation, an electrocardiogram (ECG), an echocardiogram (echo), and is confirmed via genetic testing. Definitive confirmation requires identifying a pathogenic variant in the PRKAG2 gene, which differentiates it from other conditions like hypertrophic cardiomyopathy (HCM) or Wolff-Parkinson-White (WPW) syndrome.

Prognosis

PRKAG2 syndrome is a progressive, autosomal-dominant glycogen storage disorder with a highly variable prognosis. While severe neonatal cases can be fatal, adults generally face risks of complete heart block (requiring a pacemaker), atrial fibrillation, sudden cardiac death (SCD), and advanced heart failure.

Prognosis and management largely depend on early detection and intervention, as the syndrome differs clinically and pathologically from typical sarcomeric hypertrophic cardiomyopathy (HCM).

Treatment

Management for PRKAG2 syndrome is highly individualized, focusing on symptom control and managing cardiovascular complications. Currently, there are no approved disease-modifying therapies, though precision RNA-targeting treatments (such as ATR-1072) are actively advancing through ⁠Atrium Therapeutics clinical trials.

1. Cardiac Devices
Because PRKAG2 syndrome frequently causes electrical conduction system degeneration (like heart blocks and accessory pathways), device intervention is a cornerstone of care:
  • Pacemakers: Often required for patients experiencing heart block or slow heart rhythms (bradyarrhythmias).
  • Implantable Cardioverter-Defibrillators (ICDs): Recommended for individuals with a history of dangerous ventricular arrhythmias (VT/VF) or severe left ventricular hypertrophy (LVH > 3 cm) to prevent sudden cardiac arrest.
2. Medications
Doctors prescribe medications to manage specific symptoms, arrhythmias, and heart failure:
  • Antiarrhythmics: Used to control abnormal heartbeats, such as atrial fibrillation or atrial flutter.
  • Anticoagulants: Prescribed for patients with atrial fibrillation to reduce the risk of stroke.
  • Heart Failure Medications: Standard therapies (such as ACE inhibitors or beta-blockers) are used if the thickened heart muscle progresses to heart failure.
3. Procedures & Surgery
  • Radiofrequency Catheter Ablation: Can be used to destroy extra electrical pathways in the heart, which is common in patients who develop Wolff-Parkinson-White (WPW) syndrome.
  • Heart Transplant: Required in rare, advanced cases of end-stage heart failure.